FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	hurden									

0.5

hours per response:

	Check this box if no longer subject to
	Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_		. ,				nipariy Act	0. 20		1.	· · ·			5 ():		
Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol SOLENO THERAPEUTICS INC [SLNO]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
SHAH MAHENDRA					ا										X	Direc	tor	10%	10% Owner	
(Last) (First) (Middle) C/O VIVO CAPITAL LLC						3. Date of Earliest Transaction (Month/Day/Year) 10/02/2017										Office	er (give title v)		Other (specify below)	
505 HAMILTON AVENUE, SUITE 207					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)	LTO C	A	94301												X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(;	State)	(Zip)																	
		Tab	le I - No	n-Deriv	ative	Sec	curitie	s Ac	quired	, Dis	posed o	f, o	r Ben	efici	ally C)wne	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Date						Execution Date,					ies Acquired (A) o Of (D) (Instr. 3, 4			and 5) Secu Bene Owne		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	. 17	Reported Transaction(s) (Instr. 3 and 4)			(111301. 4)	
Common Stock 10/02/2				/2017	2017			A		11,510(1)		A \$0.520		52 ⁽²⁾ 117,808		D				
		Ta									osed of, onvertib				y Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transaction Code (Instr 8)				6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		ıstr. 3	8. Prio Deriva Secur (Instr.	vative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisa	able	Expiration Date	Title	or Nu of	ount mber ares						

Explanation of Responses:

- 1. Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.
- 2. The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on September 29, 2017, or \$0.52.

Remarks:

/s/ Anish Bhatnagar, Attorneyin-Fact 10/04/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.